Skip to main content

TEVIMBRA Beigene Aus Pty Ltd

Product name
TEVIMBRA
Accepted date
Oct-2023
Active ingredients
tislelizumab
Proposed indication
For the treatment of unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (ESCC).
Application type
A (new medicine)
Publication date
Oct-2023

Help us improve the Therapeutic Goods Administration site